Sorry it didn’t land with you. We’re constantly torn between writing for the one person (a healthcare provider) vs a larger population.

An example question is a fantastic idea and will land with both audiences :-)

We’ll get our top three most recent on the homepage ASAP but in the meantime:

If you have a typical late stage COVID patient, a static patient resource like you described is perfectly fine to look at efficacy of the standard dexamethasone 6mg treatment.

But if you have an atypical patient and considering a 20mg dose, you’re out of luck. Most patients are atypical and we see an unmet need with a long tail of atypical questions.

Typical dose of dexamethasone is 6 mg not 4 mg. And only in severe cases needing oxygen, not early.

Thanks for the correction I actually typed 6 every 24 but found it confusing and resulted in error, fixed now

Also, we actually did this one, if you’re curious:

https://www.inpharmd.com/is-there-any-data-to-support-higher...

Thanks for the link. Anecdotally in our hospital only one patient to my knowledge has survived after a higher dose of dexamethasone (this was only used after the patient was worsening despite the standard 10 days of 6 mg dexamethasone). Whether this helped them or they were going to improve despite can't be known.

I would also be careful about how you use the term atypical, in fact most patients with COVID are typical and improve with the standard treatment. :)

Great info, and a shame there’s not better real world evidence for cases like this. And I hear you, just making the point that most shouldn't be considered “typical”; we should question everything.